We use highly accurate technologies to provide comprehensive diagnostic insights into a patient's tumor biology from circulating cell-free nucleic acids in the blood.
Identifying genomic drivers and targeting those specific alterations with therapy are a critical aspect of personalized medicine. Traditionally, this has been done through tissue-based mutation testing, but the landscape is evolving rapidly towards less invasive blood-based approaches. Tracking tumor-associated genetic aberrations in the blood can be used to quickly determine whether targeted therapies are a treatment option; assessing the response to therapy, presence of residual disease, recurrence, or relapse; and detecting the emergence of therapy-resistant cancer cells more quickly than conventional tissue-based methods.
We leverage Droplet Digital PCR (ddPCR™) to detect gene mutations in plasma cell-free DNA and RNA. ddPCR is highly sensitive, cost-effective, and has a fast turnaround time. Through the design of custom assays or the use of our on-market GeneStrat® test, we offer you the ability to retrospectively analyze clinical trial samples, prospectively enroll clinical trial patients, and coordinate commercialization.
Next Generation Sequencing (NGS) is a high throughput, massively parallel sequencing technique that can generate large amounts of clinically relevant data. We offer you a broad range of blood and tissue-based NGS testing solutions, including comprehensive cell-free nucleic acid assays, tumor mutation burden testing, and immune response analyses.
“The standard prognostic procedure for cancer, the tissue biopsy, is woefully inadequate — like trying to gauge a nation’s behaviour by surveying a single street. A biopsy could miss mutations just centimetres away that might radically change a person’s chances for survival. And although biopsies can provide data about specific mutations that might make a tumor vulnerable to targeted therapies, that information is static and bound to become inaccurate as the cancer evolves.”